BMI View: The incumbent Liberal-National coalition's victory in Australia's federal elections will not bring
about a clear policy direction for the healthcare sector. While the government has a fresh mandate to enact
its policies, it is considerably weaker from the pr ..."
GlobalData, the industry analysis specialist, has released its latest report, "CountryFocus: Healthcare, Regulatory and Reimbursement Landscape - Australia". The report is an essential source of information on and analysis of the healthcare, regulatory and reimbursement landsc ..."
BMI View: New Zealand's Pharmaceutical Management Agency (PHARMAC) will continue to leverage its
dominant position as a central procurer of drugs in the country to drive cost savings. While the high
standards used by the agency in its funding decisions will make the p ..."
BMI View: Innovative pharmaceutical firms will see limited upsides from New Zealand's newly adopted
health strategy for the next decade. Cost rationalisation remains a cornerstone of the government's
approach and affirms the pharmaceutical management agency's stringen ..."
BMI View: Drugmakers operating in Australia will face an increasingly challenging business environment
as the Sixth Pharmacy Community Agreement's measures come into effect. This includes a 5% price cut to
medicines listed on the F1 formulary for more than five years, ..."
BMI View: As the Australian government continues to focus on cost containment while at the same time
increasing the population's access to innovative medicines, companies will increasingly need to justify the
price of their treatments by demonstrating their value to t ..."
BMI View: The free reign that New Zealand's Pharmaceutical Management Agency (PHARMAC) has over
pharmaceutical spending will come under pressure. While the agency's stringent approach to listing
medicines has helped to curtail drug spending, it has limited access to n ..."
BMI View: New Zealand's updated Health Strategy draft will see limited improvement to the challenging
business environment for innovative drugmakers. Cost minimisation continues to be a key aspect of the
approach adopted, with the Pharmaceutical Management Agency main ..."
BMI View: The prevailing trend of austerity targeting pharmaceuticals and healthcare spending in
Australia will continue to weigh on the country's attractiveness to innovative drugmakers. On top of this,
ongoing political instability and policy uncertainty have modera ..."
BMI View: The Australian pharmaceutical market is expected to continue on a moderate growth trajectory
over our forecast period. This is mainly explained by rising chronic disease burden as well as government
funding to list new medicines under the Pharmaceutical Bene ..."